摘要
酪氨酸激酶抑制剂威罗菲尼和抗免疫抑制剂易普利单抗于2011年获美国食品药品管理局批准用于恶性黑色素瘤(MM)的治疗。通过研究靶向药物和免疫药物的耐药机制,发现肿瘤微环境、信号转导通路及细胞因子等在继发耐药中均具有重要作用。本文简要综述上述两药的继发耐药机制和克服耐药策略的研究进展。
Targeted therapy drug vemurafenib and immunotherapy drug ipilimumab were approved for the treatment of malignant melanoma （MM） in 2011. According to the further study on resistance mechanism, tumor microenvironment, signaling pathways and cell factors play an important role in the complex multi-pathway of acquired drug-resistance, which affects clinical ending point. This review summarizes the drug-resistanc mechanism of vemurafenib and ipilimumab, and addresses the new strategies to overcome this acquired drug-resistance.
出处
《世界临床药物》
CAS
2014年第6期I0005-I0008,共4页
World Clinical Drug
